These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 9762378)

  • 21. Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes.
    Reusch JE; Gadsby R
    Diabetes Technol Ther; 2003; 5(4):685-93. PubMed ID: 14511423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus.
    Palumbo PJ
    Mayo Clin Proc; 2001 Jun; 76(6):609-18. PubMed ID: 11393500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
    Kunutsor SK; Balasubramanian VG; Zaccardi F; Gillies CL; Aroda VR; Seidu S; Khunti K
    Diabetes Obes Metab; 2024 Jun; 26(6):2069-2081. PubMed ID: 38409644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of long-term complications of non-insulin-dependent diabetes mellitus.
    Nathan DM
    Clin Invest Med; 1995 Aug; 18(4):332-9. PubMed ID: 8549021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal glycemic control in type 2 diabetic patients. Does including insulin treatment mean a better outcome?
    Vaaler S
    Diabetes Care; 2000 Apr; 23 Suppl 2():B30-4. PubMed ID: 10860188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes.
    Teleb M; Popp Switzer M; Elhanafi S; Elfar A; San Juan ZT
    Curr Cardiol Rep; 2016 Mar; 18(3):29. PubMed ID: 26886228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes.
    Boyne MS; Saudek CD
    Diabetes Care; 1999 Apr; 22 Suppl 3():C45-53. PubMed ID: 10189562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.
    Hall GC; McMahon AD; Carroll D; Home PD
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):305-13. PubMed ID: 22271442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus.
    Vasudevan AR; Burns A; Fonseca VA
    Treat Endocrinol; 2006; 5(5):273-86. PubMed ID: 17002487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycemic control and complications in type 2 diabetes mellitus.
    Stolar M
    Am J Med; 2010 Mar; 123(3 Suppl):S3-11. PubMed ID: 20206730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
    Konig M; Lamos EM; Stein SA; Davis SN
    Curr Diabetes Rev; 2013 Sep; 9(5):371-81. PubMed ID: 23865412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications.
    Adams TD; Arterburn DE; Nathan DM; Eckel RH
    Diabetes Care; 2016 Jun; 39(6):912-23. PubMed ID: 27222549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
    Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
    Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Indication of intensive insulin therapy and its practice].
    Kishikawa H; Taguchi T; Matsumoto K; Shichiri M
    Nihon Rinsho; 1999 Mar; 57(3):681-7. PubMed ID: 10199154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
    Diabetes; 1995 Nov; 44(11):1249-58. PubMed ID: 7589820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.